> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bambusa Therapeutics Prices Upsized IPO At $16 A Share, Set To Raise $168.9 Million
- URL: https://www.bullished.co/bambusa-therapeutics-prices-upsized-ipo-at-16-a-share-set-to-raise-168-9-million-fa2e38ca/
- Published: 2026-10-30T00:36:05.000Z
- Updated: 2026-10-30T00:36:05.000Z
- Description: The Boston antibody developer sells all 10,555,555 shares itself, with Nasdaq trading under BBTX due to begin Friday.
- Author: Matteo Parrino
- Tags: Deals, Industry: Not classified, Topic: IPOs

Bambusa Therapeutics, a clinical-stage biotech developing long-acting bispecific antibodies for immune and inflammatory diseases, priced its upsized IPO at $16.00 a share on Thursday, [the company said](https://www.prnewswire.com/news-releases/bambusa-therapeutics-announces-pricing-of-upsized-initial-public-offering-302924376.html?ref=bullished.co). It is set to raise gross proceeds of $168,888,880 from 10,555,555 shares, before underwriting discounts and offering expenses.

## A midpoint price on a bigger deal

Every share in the offering comes from the company, so existing holders receive none of the proceeds. Shares are expected to begin trading on the Nasdaq Global Select Market on Friday under the ticker BBTX.

The $16.00 price sits at the midpoint of the $15.00 to $17.00 range marketed beforehand, and the deal was upsized from roughly 9.4 million shares first planned, according to [pre-pricing coverage](https://www.marketwatch.com/story/bambusa-therapeutics-to-sell-9-4-million-shares-at-15-17-each-in-ipo-39c7810e?ref=bullished.co).

Underwriters hold a 30-day option to buy up to [1,583,333 additional shares](https://www.prnewswire.com/news-releases/bambusa-therapeutics-announces-pricing-of-upsized-initial-public-offering-302924376.html?ref=bullished.co) at the IPO price, less discounts and commissions. That block is not counted in the base deal. BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are the joint book-running managers.

## Where the money is headed

Bambusa's lead drug, BBT001, is a bispecific antibody aimed at two inflammation targets, IL-4Rα and IL-31, and is in development for atopic dermatitis, a skin condition. In its IPO filing, the company earmarked about $90 million of proceeds for a mid-to-late-stage study of that drug, [Fierce Biotech reported](https://www.fiercebiotech.com/biotech/parkinsons-focused-aspen-and-bispecific-biotech-bambusa-both-shoot-134m-ipos?ref=bullished.co), and a further $40 million for BBT002, a second antibody.

BBT002 targets IL-4Rα and IL-5 and is in development for Type 2 inflammatory disorders. Two preclinical programs, BBT003 and BBT004, focus on gastroenterology and autoantibody-driven autoimmune diseases.

In July, [early data from 17 patients](https://www.fiercebiotech.com/biotech/parkinsons-focused-aspen-and-bispecific-biotech-bambusa-both-shoot-134m-ipos?ref=bullished.co) showed 82% of those on BBT001 reached a more than 50% improvement in eczema severity by Week 6, adjusted for placebo, per the company.

The offering is expected to close on Monday, November 2, after BBTX begins trading Friday.

### Sources

- [Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering](https://www.prnewswire.com/news-releases/bambusa-therapeutics-announces-pricing-of-upsized-initial-public-offering-302924376.html?ref=bullished.co) — PR Newswire
- [Bambusa Therapeutics to Sell 9.4 Million Shares at $15-$17 Each in IPO](https://www.marketwatch.com/story/bambusa-therapeutics-to-sell-9-4-million-shares-at-15-17-each-in-ipo-39c7810e?ref=bullished.co) — MarketWatch
- [Aspen, Bambusa both shoot for $134M IPOs](https://www.fiercebiotech.com/biotech/parkinsons-focused-aspen-and-bispecific-biotech-bambusa-both-shoot-134m-ipos?ref=bullished.co) — fiercebiotech.com
- [Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs](https://endpoints.news/aspen-bambusa-target-135m-ipos-astrazeneca-vs-takeda-in-gastric-cancer-adcs/?ref=bullished.co) — endpoints.news
- [BedRock confirms $4.1b valuation, L Catteron's Glance, and Aspen Neuroscience's IPO](https://www.axios.com/pro/all-deals/2026/10/26/pro-rata-premium-first-look-bedrock-glance-aspen?ref=bullished.co) — Axios